Cancer Research Meeting Calendar Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Research 69, 4244, May 15, 2009. Published Online First May 5, 2009;
doi: 10.1158/0008-5472.CAN-08-3521
© 2009 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Correction (v69,p8832)
Right arrow All Versions of this Article:
0008-5472.CAN-08-3521v1
69/10/4244    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singhal, S. S.
Right arrow Articles by Awasthi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singhal, S. S.
Right arrow Articles by Awasthi, S.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

RLIP76: A Target for Kidney Cancer Therapy

Sharad S. Singhal, Jyotsana Singhal, Sushma Yadav, Mukesh Sahu, Yogesh C. Awasthi and Sanjay Awasthi

Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth, Texas

Requests for reprints: Sharad S. Singhal, Department of Molecular Biology and Immunology, University of North Texas Health Science Center, 3500 Camp Bowie Boulevard, EAD Room 542, Fort Worth, TX 76107-2699. Phone: 817-735-0459; Fax: 817-735-2118; E-mail: ssinghal{at}hsc.unt.edu.

Key Words: RLIP76 • Kidney cancer • Drug resistance • Glutathione conjugate transport • Xenografts • Caki-2

RLIP76 is a multifunctional transporter protein that serves as an energy-dependent efflux mechanism for endogenously generated toxic metabolites as well as exogenous toxins, including chemotherapy drugs. Our recent studies in cultured cells, syngeneic animal tumor model, and in xenograft model have shown that RLIP76 serves a major cancer-specific antiapoptotic role in a wide variety of histologic types of cancer, including leukemia, melanoma, colon, lung, prostate, and ovarian cancer. Results of present studies in cell culture and xenograft model of Caki-2 cells show that RLIP76 is an important anticancer for kidney cancer because inhibition of RLIP76 function by antibody or its depletion by small interfering RNA or antisense DNA caused marked and sustained regression of established human kidney xenografts of Caki-2 cells in nude mouse. [Cancer Res 2009;69(10):4244–51]




This article has been cited by other articles:


Home page
 Cancer Res.Home page
Correction: RLIP76: A Target for Kidney Cancer Therapy
Cancer Res., November 15, 2009; 69(22): 8832 - 8832.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.